ERBB2 and gastric cancer: The combination of pembrolizumab and margetuximab was tested in a phase 1b/2 trial on patients with relapsed/refractory advanced HER2-neu+ PD-L1-unselected GC/GEC who failed trastuzumab therapy (Table 1; Catenacci et al., 2018).